Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...
So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...
It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...
UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicinesDAVOS/GENEVA, ...
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these drugs to those who need it most will be critical, says Beatriz Grinsztejn, ...
Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...
Over the past decades understanding and treating HIV infection has advanced tremendously. This year the drug lenacapavir, which blocks release of the viral genome in the cell and effectively prevented ...
Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.